ArticleBiology direct2018
Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.
Article in Biology direct, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Flavokawain A suppresses the malignant progression of neuroblastoma in vitro depending on inactivation of ERK/VEGF/MMPs signaling pathway.Discover oncology · 2024Article
- Expression of HECTD2 predicts peritoneal metastasis of gastric cancer and reconstructs immune microenvironment.Cancer cell international · 2024Article
- ViLoN-a multi-layer network approach to data integration demonstrated for patient stratification.Nucleic acids research · 2023Article
- Quantification of mutant-allele expression at isoform level in cancer from RNA-seq data.NAR genomics and bioinformatics · 2022Article
- Ferroptosis-related gene signatures in neuroblastoma associated with prognosis.Frontiers in cell and developmental biology · 2022Article
- Fusion Gene Detection Using Whole-Exome Sequencing Data in Cancer Patients.Frontiers in genetics · 2022Article
- Article
- Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets.Frontiers in oncology · 2021Article
- HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell CancerFrontiers in cell and developmental biology · 2021Article
- Article
- The ZNF750-RAC1 axis as potential prognostic factor for breast cancer.Cell death discovery · 2020Article
- Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?Biology direct · 2020Review
- Liquid biopsies and cancer omics.Cell death discovery · 2020Review
- Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.Nature communications · 2020Article
- Cancer predictive studies.Biology direct · 2020Review
- LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly.Genome research · 2019Article
- Role of SNHG7-miR-653-5p-STAT2 feedback loop in regulating neuroblastoma progression.Journal of cellular physiology · 2019Article
- Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.Biology direct · 2018Article
- Deep Learning-Based Multi-Omics Data Integration Reveals Two Prognostic Subtypes in High-Risk Neuroblastoma.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundNeuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression. Many studies have identified aberrations related to the pathogenesis and prognosis, broadly classifying neuroblastoma patients into high- and low-risk groups, but predicting tumor progression and clinical management of high-risk patients remains a big challenge.
resultsWe integrate gene-level expression, array-based comparative genomic hybridization and functional gene-interaction network of 145 neuroblastoma patients to detect potential driver genes. The drivers are summarized into a driver-gene score (DGscore) for each patient, and we then validate its clinical relevance in terms of association with patient survival. Focusing on a subset of 48 clinically defined high-risk patients, we identify 193 recurrent regions of copy number alterations (CNAs), resulting in 274 altered genes whose copy-number gain or loss have parallel impact on the gene expression. Using a network enrichment analysis, we detect four common driver genes, ERCC6, HECTD2, KIAA1279, EMX2, and 66 patient-specific driver genes. Patients with high DGscore, thus carrying more copy-number-altered genes with correspondingly up- or down-regulated expression and functional implications, have worse survival than those with low DGscore (P = 0.006). Furthermore, Cox proportional-hazards regression analysis shows that, adjusted for age, tumor stage and MYCN amplification, DGscore is the only significant prognostic factor for high-risk neuroblastoma patients (P = 0.008).
conclusionsIntegration of genomic copy number alteration, expression and functional interaction-network data reveals clinically relevant and prognostic putative driver genes in high-risk neuroblastoma patients. The identified putative drivers are potential drug targets for individualized therapy. REVIEWERS: This article was reviewed by Armand Valsesia, Susmita Datta and Aleksandra Gruca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.